Patents by Inventor Tatsuji Matsuoka
Tatsuji Matsuoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9856321Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.Type: GrantFiled: September 4, 2015Date of Patent: January 2, 2018Assignee: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Takeshi Takizawa, Akiko Oguni, Tatsuji Matsuoka, Hiroko Yoshida, Yumi Matsui
-
Patent number: 9714298Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: GrantFiled: April 9, 2013Date of Patent: July 25, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Publication number: 20160368990Abstract: The present invention relates to an antibody having a therapeutic effect on a tumor. That is, the invention relates to an antibody which binds to B7-H3 to exhibit an antitumor activity. An object of the invention is to provide a pharmaceutical having a therapeutic effect on a tumor. By obtaining an anti-B7-H3 antibody which binds to B7-H3 to exhibit an antitumor activity, a pharmaceutical composition for treating a tumor comprising the antibody and the like are obtained.Type: ApplicationFiled: June 20, 2016Publication date: December 22, 2016Applicant: Daiichi Sankyo Company, LimitedInventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa
-
Patent number: 9481733Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: GrantFiled: July 6, 2015Date of Patent: November 1, 2016Assignee: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Patent number: 9371395Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.Type: GrantFiled: April 24, 2012Date of Patent: June 21, 2016Assignee: Daiichi Sankyo Company, LimitedInventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa
-
Publication number: 20160068603Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.Type: ApplicationFiled: September 4, 2015Publication date: March 10, 2016Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Toshiaki Ohtsuka, Takeshi Takizawa, Akiko Oguni, Tatsuji Matsuoka, Hiroko Yoshida, Yumi Matsui
-
Publication number: 20160009820Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: ApplicationFiled: July 6, 2015Publication date: January 14, 2016Applicant: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Patent number: 9127070Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.Type: GrantFiled: October 27, 2011Date of Patent: September 8, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Takeshi Takizawa, Akiko Oguni, Tatsuji Matsuoka, Hiroko Yoshida, Yumi Matsui
-
Patent number: 9114131Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: GrantFiled: October 4, 2011Date of Patent: August 25, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Publication number: 20150125454Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: ApplicationFiled: April 9, 2013Publication date: May 7, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Publication number: 20140004120Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.Type: ApplicationFiled: October 27, 2011Publication date: January 2, 2014Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Toshiaki Ohtsuka, Takeshi Takizawa, Akiko Oguni, Tatsuji Matsuoka, Hiroko Yoshida, Yumi Matsui
-
Publication number: 20130280276Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: ApplicationFiled: October 4, 2011Publication date: October 24, 2013Inventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Publication number: 20130078234Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.Type: ApplicationFiled: April 24, 2012Publication date: March 28, 2013Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa
-
Patent number: 5407826Abstract: Trans-4-hydroxy-L-proline is produced microbially, especially by the cultivation of a microorganism of the genus Clonostachys, Gliocladium or Nectria.Type: GrantFiled: March 22, 1994Date of Patent: April 18, 1995Assignee: Sankyo Company, LimitedInventors: Tatsuji Matsuoka, Nobufusa Serizawa, Tsuyoshi Hosoya, Kouhei Furuya
-
Patent number: 5334517Abstract: Trans-4-hydroxy-L-proline is produced microbially, especially by the cultivation of a microorganism of the genus Clonostachys, Gliocladium or Nectria.Type: GrantFiled: December 15, 1992Date of Patent: August 2, 1994Assignee: Sankyo Company LimitedInventors: Tatsuji Matsuoka, Nobufusa Serizawa, Tsuyoshi Hosoya, Kouhei Furuya
-
Patent number: 5179013Abstract: Novel cytochrome P-450.sub.sca-1, P-450.sub.sca-2 and P-450.sub.sca-3 enzymes are produced by cultivation of Streptomyces carbophilus SANK 62585, and are suitable for use in hydroxylation processes.Type: GrantFiled: May 30, 1990Date of Patent: January 12, 1993Assignee: Sankyo Company, LimitedInventors: Tatsuji Matsuoka, Shunichi Miyakoshi